Impact of hepatitis B and delta virus co-infection on liver disease in Mauritania: Across sectional study

Journal of Infection

Volumn 67, Issue 5, 2013, Pages 448-457

  Lunel Fabiani, Françoise ^a,b   Mansour, Wael ^a,b,d,e   Amar, Abdellahi Ould ^c   Aye, Mohamed ^c   Le Gal, Frédéric ^d,e   Malick, F Zahra Fall ^f   Baïdy, LÔ ^f   Brichler, Ségolène ^d,e   Veillon, Pascal ^a,b   Ducancelle, Alexandra ^a,b   Gordien, Emmanuel ^d,e   Rosenheim, Michel ^g  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ D'ANGERS   (France)

^c National Hospital   (Mauritania)

^d HÔpitaux universitaires de Paris Seine Saint Denis   (France)

^e UNIVERSITÉ PARIS 13   (France)

^f National Public Health Institute   (Mauritania)

^g SORBONNE UNIVERSITÉ   (France)

Author keywords

APRI; Cirrhosis; FibroMeter; HBV; HDV; Liver fibrosis; Mauritania

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 2 MACROGLOBULIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS ANTIBODY; HEPATITIS DELTA VIRUS ANTIBODY; HYALURONIC ACID; UNCLASSIFIED DRUG; UREA; VIRUS RNA;

ADOLESCENT; ADULT; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE TO PLATELET RATIO INDEX; CROSS-SECTIONAL STUDY; DELTA AGENT HEPATITIS; DIAGNOSTIC TEST; FEMALE; FIBROMETER TEST; HEPATITIS B; HEPATOBILIARY PARAMETERS; HEPATOMEGALY; HUMAN; JAUNDICE; LIVER FAILURE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MAURITANIA; MIXED INFECTION; PHYSICAL EXAMINATION; PORTAL HYPERTENSION; PROTHROMBIN TIME; THROMBOCYTE COUNT;

APRI; CIRRHOSIS; FIBROMETER; HBV; HDV; LIVER FIBROSIS; MAURITANIA;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; COINFECTION; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS ANTIBODIES; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS D; HEPATITIS DELTA VIRUS; HUMANS; LIVER CIRRHOSIS; MALE; MAURITANIA; MIDDLE AGED; RISK FACTORS;

EID: 84884701036     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2013.06.008     Document Type: Article

References (36)

1. Gaeta G.B., Stroffolini T., Chiaramonte M., Ascione T., Stornaiuolo G., Lobello S., et al. Chronic hepatitis D: a vanishing disease? An Italian multicenter study. Hepatology 2000, 32(4 Pt 1):824-827.
2. Rizzetto M. Hepatitis D: thirty years after. J Hepatol 2009, 50(5):1043-1050.
3. Makuwa M., Mintsa-Ndong A., Souquiere S., Nkoghe D., Leroy E.M., Kazanji M. Prevalence and molecular diversity of hepatitis B virus and hepatitis delta virus in urban and rural populations in northern Gabon in central Africa. J Clin Microbiol 2009, 47(7):2265-2268.
4. Makuwa M., Caron M., Souquiere S., Malonga-Mouelet G., Mahe A., Kazanji M. Prevalence and genetic diversity of hepatitis B and delta viruses in pregnant women in Gabon: molecular evidence that hepatitis delta virus clade 8 originates from and is endemic in central Africa. J Clin Microbiol 2008, 46(2):754-756.
5. Wedemeyer H., Heidrich B., Manns M.P. Hepatitis D virus infection - not a vanishing disease in Europe!. Hepatology 2007, 45(5):1331-1332. [author reply 1332-3].
6. Foupouapouognigni Y., Noah D.N., Sartre M.T., Njouom R. High prevalence and predominance of hepatitis delta virus genotype 1 infection in Cameroon. J Clin Microbiol 2011, 49(3):1162-1164.
7. Mansour W., Bollahi M.A., Hamed C.T., Brichler S., Le Gal F., Ducancelle A., et al. Virological and epidemiological features of hepatitis delta infection among blood donors in Nouakchott, Mauritania. J Clin Virol 2012, 55(1):12-16.
8. Mansour W., Malick F.Z., Sidiya A., Ishagh E., Chekaraou M.A., Veillon P., et al. Prevalence, risk factors, and molecular epidemiology of hepatitis B and hepatitis delta virus in pregnant women and in patients in Mauritania. J Med Virol 2012, 84(8):1186-1198.
9. Romeo R., Del Ninno E., Rumi M., Russo A., Sangiovanni A., de Franchis R., et al. A 28-year study of the course of hepatitis delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology 2009, 136(5):1629-1638.
10. Buti M., Homs M., Rodriguez-Frias F., Funalleras G., Jardi R., Sauleda S., et al. Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study. J Viral Hepat 2011, 18(6):434-442.
11. Mumtaz K., Ahmed U.S., Memon S., Khawaja A., Usmani M.T., Moatter T., et al. Virological and clinical characteristics of hepatitis delta virus in South Asia. Virol J 2011, 8:312.
12. Wai C.T., Greenson J.K., Fontana R.J., Kalbfleisch J.D., Marrero J.A., Conjeevaram H.S., et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38(2):518-526.
13. Bonnard P., Sombie R., Lescure F.X., Bougouma A., Guiard-Schmid J.B., Poynard T., et al. Comparison of elastography, serum marker scores, and histology for the assessment of liver fibrosis in hepatitis B virus (HBV)-infected patients in Burkina Faso. Am J Trop Med Hyg 2010, 82(3):454-458.
14. Cales P., Oberti F., Michalak S., Hubert-Fouchard I., Rousselet M.C., Konate A., et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005, 42(6):1373-1381.
15. Mbaye P.S., Sarr A., Sire J.M., Evra M.L., Ba A., Daveiga J., et al. Liver stiffness measurement and biochemical markers in Senegalese chronic hepatitis B patients with normal ALT and high viral load. PLoS One 2011, 6(7):e22291.
16. Si Ahmed S., Mansour W., Causse X., Le Gal F., Gordien E., Fouchard-Hubert I., et al. Impact of B+Delta viruses co infection on the liver stiffness measurement (LSM) by transient elastography. J Hepatol 2008, 48(S2):249.
17. Cales P., Boursier J., Oberti F., Hubert I., Gallois Y., Rousselet M.C., et al. FibroMeters: a family of blood tests for liver fibrosis. Gastroenterol Clin Biol 2008, 32(6 Suppl. 1):40-51.
18. Le Gal F., Gordien E., Affolabi D., Hanslik T., Alloui C., Deny P., et al. Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients. J Clin Microbiol 2005, 43(5):2363-2369.
19. Radjef N., Gordien E., Ivaniushina V., Gault E., Anais P., Drugan T., et al. Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades. J Virol 2004, 78(5):2537-2544.
20. Lindh M., Gonzalez J.E., Norkrans G., Horal P. Genotyping of hepatitis B virus by restriction pattern analysis of a pre-S amplicon. J Virol Methods 1998, 72(2):163-174.
21. Abdou Chekaraou M., Brichler S., Mansour W., Le Gal F., Garba A., Deny P., et al. A novel hepatitis B virus (HBV) subgenotype D (D8) strain, resulting from recombination between genotypes D and E, is circulating in Niger along with HBV/E strains. JGen Virol 2010, 91(Pt 6):1609-1620.
22. Wedemeyer H., Manns M.P. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 2010, 7(1):31-40.
23. Yurdaydin C., Idilman R., Bozkaya H., Bozdayi A.M. Natural history and treatment of chronic delta hepatitis. J Viral Hepat 2010, 17(11):749-756.
24. Cales P., Boursier J., Bertrais S., Oberti F., Gallois Y., Fouchard-Hubert I., et al. Optimization and robustness of blood tests for liver fibrosis and cirrhosis. Clin Biochem 2010, 43(16-17):1315-1322.
25. Ozekinci T., Atmaca S., Akpolat N., Temiz H., Arikan E. Short communication: evaluation of the correlation between hepatitis D virus (HDV) RNA positivity and HDV antibodies. Mikrobiyol Bul 2005, 39(3):345-349.
26. Mederacke I., Yurdaydin C., Dalekos G.N., Bremer B., Erhardt A., Cakaloglu Y., et al. Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-alpha2a treatment. Antivir Ther 2012, 17(2):305-312.
27. Sakugawa H., Nakasone H., Nakayoshi T., Kawakami Y., Yamashiro T., Maeshiro T., et al. Hepatitis B virus concentrations in serum determined by sensitive quantitative assays in patients with established chronic hepatitis delta virus infection. J Med Virol 2001, 65(3):478-484.
28. Williams V., Brichler S., Radjef N., Lebon P., Goffard A., Hober D., et al. Hepatitis delta virus proteins repress hepatitis B virus enhancers and activate the alpha/beta interferon-inducible MxA gene. J Gen Virol 2009, 90(Pt 11):2759-2767.
29. Le Gal F., Badur S., Hawajri N.A., Akyuz F., Kaymakoglu S., Brichler S., et al. Current hepatitis delta virus type 1 (HDV1) infections in central and eastern Turkey indicate a wide genetic diversity that is probably linked to different HDV1 origins. Arch Virol 2012, 157(4):647-659.
30. Iloeje U.H., Yang H.I., Su J., Jen C.L., You S.L., Chen C.J. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130(3):678-686.
31. Chen C.J., Yang H.I. Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol 2011, 26(4):628-638.
32. Choi S.H., Jeong S.H., Hwang S.B. Large hepatitis delta antigen modulates transforming growth factor-beta signaling cascades: implication of hepatitis delta virus-induced liver fibrosis. Gastroenterology 2007, 132(1):343-357.
33. Williams V., Brichler S., Khan E., Chami M., Dény P., Kremsdorf D., et al. Large hepatitis delta antigen activates STAT-3 and NF-kB via oxidative stress. J Viral Hepat 2012, 744-753.
34. Kew M.C. Hepatocellular carcinoma in African Blacks: recent progress in etiology and pathogenesis. World J Hepatol 2010, 2(2):65-73.
35. Cainelli F. Liver diseases in developing countries. World J Hepatol 2012, 4(3):66-67.
36. Le Gal F., Gault E., Ripault M.P., Serpaggi J., Trinchet J.C., Gordien E., et al. Eighth major clade for hepatitis delta virus. Emerg Infect Dis 2006, 12(9):1447-1450.